Russell Investments Group’s ALX Oncology ALXO Stock Holding History

Russell Investments Group’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-228	Closed	-$381	–	3793
2024 Q4	$381	Buy	228 +130	+133%	+$200	﹤0.01%	3635
2024 Q3	$178	Sell	98 -2,233	-96%	-$8.3K	﹤0.01%	3647
2024 Q2	$14.1K	Buy	+2,331	New	+$28.7K	﹤0.01%	3004
2023 Q3	–	Sell	-269	Closed	-$2.02K	–	3517
2023 Q2	$2.02K	Buy	+269	New	+$1.76K	﹤0.01%	3239
2023 Q1	–	Sell	-40,813	Closed	-$460K	–	3289
2022 Q4	$460K	Hold	40,813	–	–	﹤0.01%	2320
2022 Q3	$390K	Sell	40,813 -38,774	-49%	-$452K	﹤0.01%	2338
2022 Q2	$642K	Buy	79,587 +18,587	+30%	+$202K	﹤0.01%	2162
2022 Q1	$1.03M	Buy	61,000 +19,570	+47%	+$334K	﹤0.01%	1948
2021 Q4	$889K	Buy	41,430 +11,099	+37%	+$479K	﹤0.01%	2206
2021 Q3	$2.24M	Hold	30,331	–	–	﹤0.01%	1768
2021 Q2	$1.66M	Buy	+30,331	New	+$1.82M	﹤0.01%	2031

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's ALXO Position: Q1 2025 in Review

Russell Investments Group sold out of ALX Oncology (ALXO) in Q1 2025, closing a stake of 228 shares — an estimated $381 sold.

Russell Investments Group first reported a position in ALXO in Q2 2021 and held it in 11 quarters. The position peaked at $2.24M in Q3 2021. 85 funds tracked by Wall St. Rank hold ALXO as of Q1 2025.

Russell Investments Group reported no remaining ALX Oncology position as of Q1 2025 after selling out during the quarter.
Russell Investments Group sold 228 ALX Oncology shares in Q1 2025, an estimated $381.
Russell Investments Group first reported a position in ALX Oncology in Q2 2021 and held it in 11 quarters.
Russell Investments Group's ALX Oncology position peaked at $2.24M in Q3 2021.
85 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2025.

Based on Russell Investments Group's 13F filing for Q1 2025, filed 13 May 2025.